Page 297 - Hematology_ Basic Principles and Practice ( PDFDrive )

246.e2 Part III Immunologic Basis of Hematology

53. Borrego F, Ulbrecht M, Weiss EH: Recognition of human histocompat- 78. Elliott JM, Wahle JA, Yokoyama WM: MHC class I deficient natural
ibility leukocyte antigen (HLA)-E complexed with HLA class I signal killer cells acquire a licensed phenotype after transfer into an MHC
sequence-derived peptides by CD94/NKG2 confers protection from class I-sufficient environment. J Exp Med 207:2073, 2010.
natural killer cell mediated lysis. J Exp Med 187:813, 1998. 79. Joncker NT, Shifrin N, Delebecque F, et al: Mature natural killer cells
54. Lopez-Botet M, Bellon T, Llano M, et al: Paired inhibitory and trigger- reset their responsiveness when exposed to an altered MHC environ-
ing NK cell receptors for MHC class I molecules. Hum Immunol 61:7, ment. J Exp Med 207:2065, 2010.
2000. 80. Paust S, Gill HS, Wang BZ, et al: Critical role for the chemokine recep-
55. Chang C, Detreich J, Harpur AG, et al: Cutting edge: KAP10 a novel tor CXCR6 in NK cell-mediated antigen-specific memory of haptens
transmembrane adapter protein genetically linked to DAP12 but with and viruses. Nat Immunol 11:1127, 2010.
unique signaling properties. J Immunol 163:4651, 1999. 81. Sun JC, Beilke JN, Lanier LL: Adaptive immune features of natural
56. Bauer S, Groh V, Wu J, et al: Activation of NK cells and T cells by killer cells. Nature 457:557, 2009.
NKG2D, a receptor for stress inducible MICA. Science 285:727, 1999. 82. Romee R, Schneider SE, Leong JW, et al: Cytokine activation induces
57. Ogasawara K, Lanier LL: NKG2D in NK and T cell-mediated immu- human memory-like NK cells. Blood 120:4751, 2012.
nity. J Clin Immunol 25:534, 2005. 83. Eidenschenk C, Dunne J, Jouanguy E, et al: A novel primary immu-
58. Groh V, Rhinehart R, Secrist H, et al: Broad tumor-associated expres- nodeficiency with specific natural killer cell deficiency maps to the
sion and recognition by tumor-derived γδ T cells of MICA and MICB. centromeric region of chromosome 8. Am J Hum Genet 78:721, 2006.
Proc Natl Acad Sci USA 96:6879, 1999. 84. Jawahar S, Moody C, Chan M, et al: Natural killer (NK) cell deficiency
59. Pende D, Parolini S, Pessino A, et al: Identification and molecular char- associated with an epitope-deficient Fc receptor type IIIa (CD16-II).
acterization of NKp30, a novel triggering receptor involved in natural Clin Exp Immunol 103:408, 1996.
cytotoxicity mediated by human killer cells. J Exp Med 190:1505, 85. De Vries E, Koene HR, Vossen JM, et al: Identification of an unusual Fc
1999. γ receptor IIIa (CD16) on natural killer cells in a patient with recurrent
60. Kaye J, Browne H, Stoffel M, et al: The UL16 gene of human cyto- infections. Blood 88:3022, 1996.
megalovirus encodes a glycoprotein that is dispensable for growth in 86. Orange J: Human natural killer cell deficiencies and susceptibility to
vitro. J Virol 66:6609, 1992. infection. Microbes Infect 4:1545, 2002.
61. Cosman D, Mullberg J, Sutherland CL, et al: ULBPs, novel MHC class 87. Wendlend T, Herren S, Yawalkar A, et al: Strong αβ and γδ TCR
I-related molecules, bind to CMV glycoprotein UL-16 and stimulate response in a patient with disseminated Mycobacterium avium infec-
NK cytotoxicity through the NKG2D receptor. Immunity 14:123, tion and lack of NK cells and monocytopenia. Immunol Lett 72:75,
2001. 2000.
62. Dunn C, Chalupny NJ, Sutherland CL, et al: Human cytomegalovirus 88. Ballas Z, Turner JM, Turner DA, et al: A patient with simultaneous
−
+
+
glycoprotein UL16 causes intracellular sequestration of NKG2D absence of “classical” natural killer cells (CD3 ,CD16 and NKH1 )
−
+
+
−
ligands, protecting against natural killer cell cytotoxicity. J Exp Med and expansion of CD3 , CD4 , CD8 , NKH1 subset. J Allergy Clin
197:1427, 2003. Immunol 85:453, 1990.
63. Groh V, Wu J, Yee C, et al: Tumour-derived soluble MIC ligands impair 89. Takahashi K, Miyake S, Kondo T, et al: Natural killer type 2 bias in
expression of NKG2D and T-cell activation. Nature 419:734, 2002. remission of multiple sclerosis. J Clin Invest 107:23, 2001.
64. Waldhauer I, Steinle A: Proteolytic release of soluble UL16-binding 90. Fort MM, Leach MW, Rennick DM: A role for NK cells as regulators
+
protein 2 from tumor cells. Cancer Res 66:2520, 2006. of CD4 T cells in a transfer model of colitis. J Immunol 161:3256,
65. Raffaghello L, Prigione I, Airoldi I, et al: Downregulation and/or release 1998.
of NKG2D ligands as immune evasion strategy of human neuroblas- 91. Smeltz RB, Wolf NA, Swanborg RH: Inhibition of autoimmune T cell
toma. Neoplasia 6:558, 2004. responses in the DA rat by bone marrow-derived NK cells in vitro:
66. Sutherland CL, Rabinovich B, Chalupny NJ, et al: ULBPs, human Implications for autoimmunity. J Immunol 163:1390, 1999.
ligands of NKG2D receptor, stimulate tumor immunity with enhance- 92. Flodstrom M, Maday A, Balakrishna D, et al: Target cell defense pre-
ment of IL-15. Blood 108:1313, 2006. vents the development of diabetes after viral infection. Nat Immunol
67. Sivori S, Vitale M, Morelli L, et al: p46, a novel natural killer cell- 3:373, 2002.
specific surface molecule that mediates cell activation. J Exp Med 93. Gur C, Enk J, Weitman E, et al: The expression of the β-cell derived
186:1129, 1997. autoimmune ligand for the killer receptor NKp46 is attenuated in type
68. Vitale M, Bottino C, Sivori S, et al: NKp44, a novel triggering surface 2 diabetes. PLoS ONE 8:e74033, 2013.
molecule specifically expressed by activated natural killer cells, is 94. Shi FD, Wang HB, Li H, et al: Natural killer cells determine the
involved in non-major histocompatibility complex restricted tumor outcome of B cell-mediated autoimmunity. Nat Immunol 1:245,
cell lysis. J Exp Med 187:2065, 1998. 2000.
69. Mandelboim O, Lieberman N, Lev M, et al: Recognition of hemag- 95. Groh V, Bruhl A, El-Gabalawy H, et al: Stimulation of T cell autore-
glutinins on virus-infected cells by NKp46 activates lysis by human NK activity by anomalous expression of NKG2D and its MIC ligands in
cells. Nature 409:1055, 2001. rheumatoid arthritis. Proc Natl Acad Sci USA 100:9452, 2003.
70. O’Connor GM, Hart OM, Gardiner CM: Putting the natural killer 96. Jie HB, Sarvetnick N: The role of NK cells and NK cell receptors in
cell in its place. Immunology 117:1, 2006. autoimmune disease. Autoimmunity 37:147, 2004.
71. Moretta A, Bottino C, Vitale M, et al: Activating receptors and corecep- 97. Pridegon C, Lennon GP, Pazmany L, et al: Natural killer cells in the
tors involved in human natural killer cell-mediated cytolysis. Annu Rev synovial fluid of rheumatoid arthritis patients exhibit a CD56 bright ,
Immunol 19:197, 2001. CD94 bright , CD158 negative phenotype. Rheumatology (Oxford) 42:870,
72. Brandt CS, Baratin M, Yu EC, et al: The B7 family member B7-H6 is 2003.
a tumor cell ligand for the activating natural killer cell receptor NKp30 98. De Haas M, Koene HR, Kleijer E, et al: A triallelic Fcγ receptor type
in humans. J Exp Med 206:1495, 2009. IIIA polymorphism influences the binding of human IgG by NK cell
73. Kruse PH, Matta J, Ugolini S, et al: Natural cytotoxicity receptors and FcγRIIIA. J Immunol 156:2948, 1996.
their ligands. Immunol Cell Biol 92:221, 2014. 99. Wu J, Song Y, Bakker B, et al: An activating immunoreceptor complex
74. Viver E, Raulet DH, Moretta A, et al: Innate or adaptive immunity? is formed by NKG2D and DAP10. Science 285:730, 1999.
The example of natural killer cells. Science 331:44, 2011. 100. Edberg JC, Langefeld CD, Wu J, et al: Genetic linkage and association
75. Parham P: MHC class I molecules and KIRs in human history, health of Fcγ receptor IIIA (CD16A) on chromosome 1q23 with human
and survival. Nat Rev Immunol 5:201, 2005. systemic lupus erythematosus. Arthritis Rheum 46:2132, 2002.
76. Anfossi N, Andre P, Guia S, et al: Human NK cell education by inhibi- 101. Morgan AW, Keyte VH, Babbage SJ, et al: FcγRIIIA-158V and rheu-
tory receptors for MHC class I. Immunity 25:331, 2006. matoid arthritis: A confirmation study. Rheumatology 42:528, 2003.
77. Raulet DH, Vance RE: Self-tolerance of natural killer cells. Nat Rev 102. Klingmann HG: Natural killer cell-based immunotherapeutic strate-
Immunol 6:520, 2006. gies. Cytotherapy 7:16, 2005.